Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD PharmaTimesEarly safety and efficacy signals support move into repeatdose phase 2a trialOphthalmologyRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) PharmaTimes Early safety and efficacy signals support move into repeatdose phase 2a trial Ophthalmology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly, Gilead lead pharma’s M&A boomNext: BMS’ Sotyktu secures EC approval for psoriatic arthritis Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
